Laura Catalini

Mrs. Laura Catalini

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2020 in Biology of Reproduction
Verified
Journal Article
Open access
PDF file
LCLaura Catalini
Laura Catalini
Jens FedderJens Fedder
Jens Fedder
Here we have summarized what is currently known about menstruating animal species with special emphasis on non-primate species: length of their menstrual cycle, ovulation, implantation, placentation, decidualization, and endometrial characteristics. Having an overview of all the possible animal models that can be used to study menstruation and the menstrual cycle could be useful to select the one that better matches the needs of the individual research projects. The most promising species to study menstruation seems to be the spiny mouse Acomys cahirinus. It is a rodent that could be easily held in the existing laboratory facilities for rats and mice but with the great advantage of having spontaneous menstruation and several human-like menstrual cycle characteristics. Among the species of menstruating bats, the black mastiff bat Molossus ater and wild fulvous fruit bat Rousettus leschenaultii are the ones presenting the most human-like characteristics. The elephant shrew seems to be the less suitable species among the ones analyzed. The induced mouse model of menstruation is also presented as an adaptable alternative to study menstruation.

1 February 2018 in Neurobiology of Aging
Verified
Journal Article
Closed access
EGEugenio Gutiérrez-Jiménez
Eugenio Gutiérrez-Jiménez
HAHugo Angleys
Hugo Angleys
PRPeter M. Rasmussen
Peter M. Rasmussen
MWMark J. West
Mark J. West
LCLaura Catalini
Laura Catalini
LØLeif Østergaard
Leif Østergaard

5 June 2017 in Pflügers Archiv - European Journal of Physiology
Verified
Journal Article
Closed access
PDF file
FTFrancesco Trepiccione
Francesco Trepiccione
FIFrancesco Maria Iena
Francesco Maria Iena
LCLaura Catalini
Laura Catalini
FCFrancesco Martino Carpi
Francesco Martino Carpi
MKMogens Koed
Mogens Koed
SFSebastian Frische
Sebastian Frische

30 April 2024 in Molecular Human Reproduction
Verified
Journal Article
Open access
PDF file
LCLaura Catalini
Laura Catalini
MBMark Burton
Mark Burton
DEDorte L Egeberg
Dorte L Egeberg
TETilde V Eskildsen
Tilde V Eskildsen
MTMads Thomassen
Mads Thomassen
Jens FedderJens Fedder
Jens Fedder
Studies in humans and animals suggest that seminal plasma, the acellular seminal fluid component, stimulates the endometrium to promote immune tolerance and facilitate implantation. We designed a randomized, double-blinded, placebo-controlled trial to investigate changes in the endometrial transcriptomic profile after vaginal application of seminal plasma. The study participants were randomized into two groups. Five women received a vaginal application of seminal plasma, and four received a placebo application with saline solution. The application was performed 2 days after HCG-triggered ovulation in an unstimulated cycle. After 5–8 days, an endometrial biopsy was collected to analyze differences in the endometrial transcriptomic profile using microarray analyses. A differential gene expression analysis and a gene set analysis were performed. The gene set enrichment analysis showed a positive enrichment of pathways associated with the immune response, cell viability, proliferation, and cellular movement. Moreover, pathways involved in implantation, embryo development, oocyte maturation, and angiogenesis were positively enriched. The differential gene expression analysis, after adjusting for multiple testing, showed no significantly differentially expressed genes between the two groups. A comparative analysis was also performed with similar studies conducted in other animals or in vitro using human endometrial cells. The comparative analysis showed that the effect of seminal plasma effect on the endometrium is similar in pigs, mice, and in vitro human endometrial cells. The present study provides evidence that seminal plasma might impact the endometrium during the implantation window, with potential to affect endometrial receptivity and embryo development.

1 June 2021 in Clinical Epidemiology
Verified
Journal Article
Open access
PDF file
BNBente Mertz Nørgård
Bente Mertz Nørgård
LCLaura Catalini
Laura Catalini
LJLine Riis Jølving
Line Riis Jølving
MLMichael Due Larsen
Michael Due Larsen
SFSonia Friedman
Sonia Friedman
Jens FedderJens Fedder
Jens Fedder
Assisted reproductive technology (ART) treatments in women with underlying chronic diseases have become increasingly frequent. The objective of this review is to provide an overview of the literature examining the chance of having a live born child after ART in women with chronic diseases, compared to other women receiving ART. We focused on some of the most prevalent chronic diseases in women during their reproductive years, ie ulcerative colitis, Crohn’s disease, rheumatoid arthritis, multiple sclerosis, epilepsy, hyperthyroidism, hypothyroidism, and diabetes mellitus. Secondly, we studied the chance of successful implantation. The literature search was performed in the database Pubmed.gov. including all studies published before October 2020. Title and abstracts of 58 papers were reviewed, 37 papers were excluded and other 8 studies were excluded after full-text evaluation. Only 13 papers were eligible for review. Results indicate that women with ulcerative colitis, Crohn’s disease, rheumatoid arthritis, hyperthyroidism, and diabetes mellitus type 2 might have problems with low implantation rate or early embryo development during ART. On the contrary, the few studies on women with hypothyroidism, diabetes mellitus type 1, and epilepsy suggest an equivalent chance of a live birth compared to other women undergoing ART. A possible explanation behind these differences could reside in the disease-specific dysregulation of the innate or adaptive immune system. To our knowledge, this is the first review on ART in women with chronic diseases, and it has disclosed that the evidence in this area is indeed sparse. We encourage others to examine live birth after ART in women with chronic diseases.

10 August 2022 in Health Science Reports
Verified
Journal Article
Open access
KTKathrine Tufvesson
Kathrine Tufvesson
LCLaura Catalini
Laura Catalini
Jens FedderJens Fedder
Jens Fedder
Background and Aims: The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is known to affect multiple organs by binding to angiotensin‐converting enzyme 2 receptors and might therefore affect male fertility. This review aims to collect all original articles on the effects of SARS‐CoV‐2 infection on male fertility, including the duration of time after infection required for these effects to begin to manifest and recommend how clinicians should approach cases with a recent illness.Methods: This review was developed according to the preferred reporting items for systematic reviews and meta‐analyses guidelines. The search string was applied to four online databases—namely Pubmed, Embase, Medline, and the Cochrane COVID‐19 Register—and screened using the online tool Covidence.org. Articles were eligible for inclusion if they were cohort studies involving a healthy male population diagnosed with COVID‐19, each of whom had semen samples collected before and after the infection or two different semen samples collected after the diagnosis.Results: Nine cohort studies were eventually included. Five articles had pre‐ and post‐COVID‐19 data while four had two sets of post‐COVID‐19 data. The three largest studies found a statistically significant decrease in all semen parameters when waiting less than 3 months from diagnosis before sample collection, and no significant differences in results when the ejaculate was analyzed more than 3 months after recovery. One study compared the COVID‐19 patients with a control group and found a significant decrease in semen parameters in the COVID‐19 group.Conclusion: Spermatogenesis seems to be affected by SARS‐CoV‐2 infection, but the impact tends to reverse within 3–4 months. It is still unclear why male fertility is affected by SARS‐CoV‐2 infection, and it might be the result of several different components. Clinicians should consider recent SARS‐CoV‐2 infection as a possible reason for the low semen quality of patients' semen samples, and might therefore need to collect new samples after 4 months before further treatment.